Biotechnology Irish immuno-oncology specialist ALX Oncology has entered into a clinical trial collaboration and supply agreement with us pharma major Eli Lilly to evaluate the combination of ALX148, a next generation CD47 blocker, and Cyramza (ramucirumab), Lilly’s anti-VEGFR2 antibody, for the treatment of patients with HER2-positive gastric cancer or gastroesophageal junction cancer. 10 June 2021